Author/Authors :
Conrad Santini، نويسنده , , Gregory D. Berger، نويسنده , , Wei Han، نويسنده , , Ralph Mosley، نويسنده , , Karen MacNaul، نويسنده , , Joel Berger، نويسنده , , Thomas Doebber، نويسنده , , Margaret Wu، نويسنده , , David E. Moller، نويسنده , , Richard L. Tolman، نويسنده , , Soumya P. Sahoo، نويسنده ,
Abstract :
Beginning with the weakly active lead structure 1, a new series of hPPAR agonists was developed. In vivo glucose and triglyceride lowering activity was obtained by homologation and oxamination to 3, then conversion to substituted benzisoxazoles 4 and 5. Further manipulation afforded benzofurans 6 and 7. Compound 7 was of comparable potency as a glucose and triglyceride lowering agent in insulin resistant rodents to BRL 49653.
